There is no such hormone as GLP-3. When people say "GLP-3 agonist," they almost always mean a triple receptor agonist — a single molecule engineered to activate the GIP, GLP-1, and glucagon receptors simultaneously. This page unpacks the receptor pharmacology behind that shorthand, the published clinical data on retatrutide, and the wider multi-agonist pipeline — with every claim attributed to its source. No triple agonist is approved anywhere in the world, and nothing sold under this label today is legal medicine.
Talk to a Licensed Clinician Read the PharmacologyThe term is a nomenclature accident — but it points at a real and genuinely interesting class of drugs. Understanding why the shorthand exists requires a quick tour of incretin biology.
The proglucagon gene gives rise to several peptide hormones, including glucagon, GLP-1 (glucagon-like peptide-1), and GLP-2 (glucagon-like peptide-2). GLP-1 is an incretin: a gut hormone released after eating that amplifies glucose-dependent insulin secretion from pancreatic beta cells. GLP-2 exists too, but it acts mainly on intestinal growth and barrier function, not appetite or glycemia. GLP-3 does not exist. No such peptide has been identified in human physiology, and no pharmaceutical company has a molecule by that name.
So where did the term come from? Naming drift. Semaglutide made "GLP-1" a household word. Tirzepatide, which adds a second receptor target, got casually branded "GLP-2" in some corners of the internet — also wrong, since GLP-2 is a real, unrelated hormone. By extension, the three-receptor drugs in development became "GLP-3 agonists" in forums, group chats, and grey-market marketing copy. The arithmetic is intuitive and the pharmacology is wrong. The correct term is triple agonist, triple receptor agonist, or GIP/GLP-1/glucagon receptor triagonist.
In practice, "GLP-3 agonist" almost always refers to retatrutide, Eli Lilly's investigational molecule LY-3437943 — a single unimolecular peptide engineered to act as an agonist at three distinct receptors: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). One molecule, three binding targets, three overlapping arms of metabolic physiology.
That distinction matters more than pedantry. A search for "GLP-3" surfaces a swamp of unregulated peptide vendors using the pseudo-category to sell unapproved compounds. Knowing that the real class is called triple agonism — and that its lead molecule is still in phase 3 clinical trials — is the fastest way to tell published science from marketing fiction. Everything below is drawn from peer-reviewed publications and registered trial records, cited as we go.
Each receptor contributes a distinct piece of metabolic signaling. The design rationale for triple agonism, laid out in the peer-reviewed literature on the class, is that activating all three together produces effects no single- or dual-receptor drug fully replicates.
GLP-1 receptor agonism is the established backbone of the class. Activating GLP-1R enhances glucose-dependent insulin secretion — insulin is released when blood glucose is elevated, which is why the incretin mechanism carries a low intrinsic hypoglycemia risk in people not on insulin. It also suppresses glucagon release when glucose is high, delays gastric emptying, and signals satiety centrally, reducing appetite and energy intake.
This is the receptor behind semaglutide (marketed as Wegovy and Ozempic) and liraglutide before it. Large outcome trials of GLP-1 receptor agonists, including SELECT and FLOW for semaglutide, have documented cardiovascular and kidney benefits — which is part of why regulators and researchers treat the receptor family so seriously.
GIP — glucose-dependent insulinotropic polypeptide — is the other incretin hormone, secreted by K-cells in the upper small intestine. Like GLP-1, GIP receptor activation stimulates glucose-dependent insulin release. The review literature on multi-agonists also describes a role for GIPR signaling in appetite regulation and, notably, in tolerability: GIP receptor agonism appears to dampen the hindbrain circuits that drive nausea and emesis, potentially offsetting the most common side effect of GLP-1 receptor agonists.
GIP/GLP-1 dual agonism is already validated in an approved drug: tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes), which outperformed pure GLP-1 agonism in its SURPASS and SURMOUNT trial programs. The GIP receptor is the reason tirzepatide is not just "a stronger semaglutide" — it is mechanistically a different animal.
The third receptor is the counterintuitive one. Glucagon raises blood glucose — so why agonize its receptor in a metabolic drug? Because glucagon receptor activation does more than mobilize glucose: the published literature on the class attributes increased whole-body energy expenditure, enhanced hepatic lipid oxidation, reduced liver fat accumulation, and brown adipose tissue activation to GCGR agonism, along with an appetite-reducing effect of its own.
In a triple agonist, the glycemic cost of glucagon signaling is designed to be counterbalanced by the two incretin arms driving insulin secretion. The intended net effect: burn more energy while eating less, without losing glucose control. Whether that balance holds at scale is precisely what phase 3 trials exist to determine — energy expenditure claims in humans remain an area of active investigation, not settled fact.
Retatrutide (LY-3437943) is Eli Lilly's unimolecular GIP/GLP-1/glucagon receptor triagonist and the most advanced molecule in the class. It is investigational: not approved by the FDA, the EMA, or any other regulator, for any indication.
The numbers that made the internet care were published in the New England Journal of Medicine in 2023. In a 48-week phase 2 obesity trial of 338 adults, participants in the highest-dose arm had a mean body weight change of -24.2%, versus -2.1% for placebo. In the same arm, 64% of participants lost at least 20% of body weight and roughly a quarter lost 30% or more. Waist circumference fell by a mean of 19.6 cm, and reductions in systolic blood pressure, triglycerides, and LDL cholesterol were reported alongside.
A separate 36-week phase 2 trial in type 2 diabetes reported mean weight change of -16.9% and HbA1c reduction of -2.2% in the highest-dose arm, against an active comparator (dulaglutide) that achieved -1.4%. A liver-fat substudy in participants with MASLD reported liver fat reductions exceeding 80% at the top dose, with the majority of that arm reaching normal liver fat content. Gastrointestinal adverse events — nausea, vomiting, diarrhea — were the most common side effects, consistent with the incretin class, and dose-dependent.
Phase 2 results, however striking, are not approval. Retatrutide is now in a large phase 3 program registered on ClinicalTrials.gov under the TRIUMPH name: TRIUMPH-1 through TRIUMPH-6 span obesity alone, obesity with type 2 diabetes, obesity with established cardiovascular disease, obesity with knee osteoarthritis, obstructive sleep apnea populations, a head-to-head trial against tirzepatide (TRIUMPH-5), and a long-term maintenance study. TRIUMPH-OUTCOMES (NCT06383390) is a cardiovascular and renal outcomes trial enrolling on the order of 10,000 participants.
A parallel phase 3 program in type 2 diabetes, TRANSCEND-T2D, includes a head-to-head trial against semaglutide and a trial in chronic kidney disease patients on basal insulin. This is the standard arc for a molecule with blockbuster ambitions: efficacy first, then years of safety, durability, and outcomes evidence across the populations who would actually use it. Until that program reads out and regulators review it, retatrutide remains an experimental compound available only inside registered clinical trials.
Retatrutide is the furthest along, but it is not alone. A 2025 peer-reviewed review of triple agonism therapies for obesity maps a crowded field of unimolecular multi-agonists in clinical development. Every molecule named here is investigational unless stated otherwise.
Beyond retatrutide, the review identifies several GIP/GLP-1/glucagon triagonists in earlier development: UBT251 and MWN-101 in phase 2 territory, and efocipegtrutide (HM-15211), a triple agonist being studied primarily in liver disease rather than obesity. Sanofi's SAR441255 completed phase 1 but has no reported trials since. Attrition is the norm here — a phase 1 or 2 molecule is a hypothesis, not a product, and most hypotheses in this field die quietly.
A parallel branch skips GIP and pairs GLP-1 with glucagon receptor agonism. The same review covers mazdutide and survodutide, both in phase 3, with published mid-stage weight reductions in the 15-19% range over roughly a year; pemvidutide, which completed phase 2 (the MOMENTUM trial); and efinopegdutide, whose phase 2a data showed liver fat reductions substantially exceeding semaglutide's at similar weight loss — a signal that the glucagon arm earns its keep in hepatic metabolism specifically.
The frontier keeps moving. The review also describes DR-10624, which swaps GIP for an FGF-21 receptor arm and targets severe hypertriglyceridemia; bioglutide, a quadruple agonist adding IGF-1 signaling; and combination strategies stacking tirzepatide with agents like eloralintide (an amylin receptor agonist) or mibavademab (a leptin receptor agonist). The lesson of the pipeline is that "GLP-3" undersells what is happening: the field is not counting up a number, it is combinatorially exploring receptor biology.
The approved incretin drugs form a natural comparison ladder — with one large caveat: these numbers come from different trials with different populations, durations, and designs. Cross-trial comparison is directional, not definitive. Only head-to-head trials like TRIUMPH-5 settle rankings.
Mono-agonism: semaglutide, a pure GLP-1 receptor agonist, produced 14.9% mean weight loss over 68 weeks in the STEP-1 trial versus 2.4% for placebo. Dual agonism: tirzepatide, the GIP/GLP-1 dual agonist, produced 20.9% over 72 weeks in SURMOUNT-1 versus 3.1% for placebo. Triple agonism: retatrutide's phase 2 reported -24.2% at just 48 weeks — a shorter trial that had not yet reached a weight plateau, which is part of why expectations for its phase 3 data run high.
Each added receptor has, so far, shifted the efficacy distribution upward. The mechanistic story is coherent: GLP-1 restrains intake, GIP adds insulinotropic signaling and appears to improve tolerability, and glucagon adds an energy-expenditure and hepatic arm that neither incretin provides. But phase 2 populations are smaller and more selected than phase 3 ones, and effect sizes routinely shrink as trials scale. Treat the ladder as a hypothesis with good early support.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are FDA-approved, manufactured under pharmaceutical GMP conditions, dispensed by licensed pharmacies, and prescribed by clinicians who monitor for the class's known risks. Retatrutide and every other molecule in the previous section have none of that scaffolding. Approval is not a formality — it is the difference between a characterized medicine and an experimental compound.
This is also why the comparison question people actually ask — "should I wait for the triple agonist?" — is a clinical conversation, not a spreadsheet exercise. Two highly effective incretin medicines are approved and available today through legitimate medical channels. Anyone weighing them against an unapproved molecule with incomplete safety data should be having that conversation with a licensed clinician, not a peptide forum.
This is the part the grey market would prefer you skip. As of this writing, no GIP/GLP-1/glucagon triple agonist has been approved by any regulatory authority in the world.
Because the phase 2 data went viral, an illegal market emerged years ahead of any approval: online vendors selling vials labeled "retatrutide" or "GLP-3" as so-called research chemicals, compounding operations producing unauthorized copies, and med-spas offering injections of an unapproved investigational drug. On August 12, 2026, Eli Lilly filed lawsuits against six U.S. companies — including compounding pharmacies, medical spas, and online peptide sellers — over illegal sales of purported retatrutide, as reported by CNBC, BioPharma Dive, and Fierce Pharma. Lilly has separately reported more than 200 entities involved in this market to the FDA, the Department of Justice, and state authorities, per those same reports.
The legal logic is simple: there is no lawful source of retatrutide outside a registered clinical trial. Lilly does not sell its active pharmaceutical ingredient to third parties. Whatever is in a grey-market vial, its identity, purity, dose accuracy, and sterility are unverified by any regulator — and U.S. Customs seizure figures cited in the same coverage suggest the counterfeit volume is large and growing. "Research use only" labels do not change any of this; they are a disclaimer costume on an illegal product.
This is an independent educational resource about the pharmacology and clinical development of multi-receptor agonists. It is not affiliated with, endorsed by, or connected to Eli Lilly and Company or any pharmaceutical manufacturer. Nothing here is medical advice, and nothing here should be read as guidance on obtaining, dosing, or using any compound — approved or otherwise. We deliberately do not cover sourcing, vendors, or administration, because for an unapproved investigational drug there is no safe or legal version of that information.
If the science on this page is relevant to your health — if you have obesity, type 2 diabetes, or metabolic disease and the incretin class sounds like something that could help — the correct next step is a licensed clinician. Approved options exist now. Clinical trials of the newer molecules recruit through ClinicalTrials.gov and enroll under informed consent with medical oversight. Those are the two legitimate doors into this class of medicine, and they are the only two.
No. The proglucagon gene produces glucagon, GLP-1, and GLP-2 — there is no GLP-3 in human physiology. "GLP-3 agonist" is informal internet shorthand for triple receptor agonists: single molecules that activate the GIP, GLP-1, and glucagon receptors simultaneously. The correct terminology is triple agonist or GIP/GLP-1/glucagon receptor triagonist, and the best-known example is retatrutide (Eli Lilly's LY-3437943), currently in phase 3 trials.
Cross-trial comparisons are inherently imperfect, but the published record reads: semaglutide (GLP-1 mono-agonist) reached 14.9% mean weight loss over 68 weeks in STEP-1; tirzepatide (GIP/GLP-1 dual agonist) reached 20.9% over 72 weeks in SURMOUNT-1; and retatrutide's 48-week phase 2 trial, published in the New England Journal of Medicine in 2023, reported -24.2% in its highest-dose arm — without a weight plateau at trial's end. Retatrutide's numbers come from a smaller, shorter phase 2, so the definitive answer awaits head-to-head phase 3 data such as TRIUMPH-5, which compares retatrutide directly against tirzepatide.
Only by enrolling in a registered clinical trial. No triple agonist is approved by the FDA or any other regulator, so there is no legal prescription, pharmacy, or compounded version anywhere. The TRIUMPH and TRANSCEND-T2D phase 3 programs recruit through ClinicalTrials.gov listings. Anything sold online as "retatrutide" or a "GLP-3 agonist" is illegal and unverified — Eli Lilly sued six such sellers on August 12, 2026, and has reported over 200 entities to regulators, according to news coverage of the filings. If you want treatment now, semaglutide and tirzepatide are approved incretin medicines available through licensed clinicians.
It does — glucagon mobilizes hepatic glucose. The design bet of triple agonism, described in the peer-reviewed literature on the class, is that the two incretin arms (GLP-1 and GIP driving glucose-dependent insulin secretion) counterbalance that effect, while glucagon receptor agonism contributes what incretins cannot: increased energy expenditure, enhanced hepatic fat oxidation, and large reductions in liver fat. Retatrutide's phase 2 diabetes trial reported an HbA1c reduction of 2.2 percentage points in its highest-dose arm, suggesting the balance held in that study — but confirming it at scale is a core job of the ongoing phase 3 program.
Tirzepatide (Zepbound, Mounjaro) is a dual agonist: it activates the GIP and GLP-1 receptors. A triple agonist like retatrutide adds a third pharmacology — glucagon receptor agonism — which the literature associates with increased energy expenditure and pronounced hepatic effects, including liver fat reduction. Tirzepatide is FDA-approved and available by prescription; retatrutide is investigational, unapproved, and available only within clinical trials. TRIUMPH-5 is testing the two head-to-head.
Unknown. Approval depends on the TRIUMPH and TRANSCEND-T2D phase 3 programs reading out successfully and on regulatory review after that — neither of which has a guaranteed outcome or public completion date. Phase 2 success does not assure phase 3 success, and several molecules in this class have stalled after promising early data. Any website or seller implying retatrutide is available now, or approved anywhere, is misrepresenting an experimental compound.
The Agency Behind This Site
You found this page because it ranks for the exact term you searched. That is the point. SEO Jesus builds exact-match educational sites like this one as live demonstrations of search engine optimization done properly: deep topical coverage, structured data, clean on-page architecture, and content that actually answers the query better than what ranked before it. If a standalone page can rank for "GLP-3 agonist," imagine what the same process does for a business's own website.
SEO Jesus is a specialist SEO agency working exclusively in search. This site is part of a public case study in ranking niche educational content with an AI-orchestrated build process — researched, written, assembled, and deployed by an agent swarm, then measured in the open. It is an independent educational resource: not affiliated with Eli Lilly and Company, not selling anything in this niche, and not a substitute for medical advice.
Book a Strategy Call With SEO Jesus →This page explains pharmacology; it cannot examine you. If you are considering treatment for obesity, type 2 diabetes, or metabolic disease, licensed telehealth and in-person clinicians can evaluate whether an approved incretin medicine is appropriate for you — and they are the only legitimate path to this class of drugs. Medical disclaimer: this site is an independent educational resource, is not affiliated with Eli Lilly and Company, and provides no medical advice, dosing information, or sourcing guidance.
Find Licensed Telehealth Care (HHS)